Latest Financial Results

Q3 2017

Quarterly Results

Quarter Ended Sep 30, 2017

Sign up for email alerts

Be the first to receive breaking news

Sign up today

Stock Information Data is 15 minutes delayed

ContraFect Corporation — Common Stock NASDAQ: CFRX
Market Cap
ContraFect Corporation — Class A Warrants NASDAQ: CFRXW
52 Week Low/High

Company Overview

ContraFect Corporation is a clinical stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Drug resistant infections cause 2 million illnesses in the U.S. and 700,000 deaths worldwide each year. Our therapeutic product candidates from our lysin and monoclonal antibody platforms are intended to address drug-resistant infections through novel mechanisms which are highly targeted towards conserved regions of either bacteria or viruses (regions that are not prone to mutation).